Atezolizumab Approved in Europe for Lung, Bladder Cancer

September 25, 2017 – The European Commission has granted regulatory approval to atezolizumab monotherapy for the treatment of patients with previously-treated locally advanced or metastatic non–small cell lung cancer (NSCLC) and previously-treated locally advanced or metastatic urothelial carcinoma (mUC). The drug is indicated following chemotherapy for patients with NSCLC regardless of PD-L1 status. Patients with EGFR-activating mutations or ALK-positive … (leggi tutto)